- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07529808
Estudio de Fase 1/2 de BHB810 en Adenocarcinoma Gástrico Avanzado y de la Unión Gastroesofágica
Estudio de Fase 1/2, Abierto, Multicéntrico, de Escalada de Dosis y Expansión de BHB810 en Participantes con Adenocarcinoma Gástrico Avanzado y de la Unión Gastroesofágica
This study is looking at how safe BHB810 is in adults with gastric and gastroesophageal adenocarcinoma (GEJ). The purpose of this study is also to look at: how well the study drug works, how the study drug moves into, through, and out of the body, and how your body reacts to the study drug. Participants will get an IV infusion of BHB810 every 2 weeks while on study treatment.
Descripción general del estudio
Estado
Condiciones
- Cáncer gástrico
- Cancer de pancreas
- Adenocarcinoma gástrico
- Adenocarcinoma gastroesofágico
- Cáncer gástrico avanzado
- Cáncer colorrectal (colon o recto)
- Cánceres gastrointestinales
- Cáncer gástrico (de estómago)
- Cáncer gastrointestinal metastásico
- Adenocarcinoma de la unión gastroesofágica (UGE)
- Cáncer Gastroesofágico (CG)
- Cáncer de la unión gastroesofágica (UGE)
- Adenocarcinoma gastrointestinal
- Tumores sólidos avanzados positivos para CDH17
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Duarte, California, Estados Unidos, 91010
- Reclutamiento
- City of Hope Duarte
-
Investigador principal:
- Dani Castillo, MD
-
Contacto:
- Jalene Tangen
- Número de teléfono: 833-917-5715
- Correo electrónico: jtangen@coh.org
-
Santa Monica, California, Estados Unidos, 90404
- Aún no reclutando
- University of California at Los Angeles
-
Investigador principal:
- Zev Wainberg, MD
-
Contacto:
- Rachel Andes
- Número de teléfono: 16122 310-633-8400
- Correo electrónico: randes@mednet.ucla.edu
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Reclutamiento
- NEXT Virginia
-
Investigador principal:
- Alexander Spira, MD
-
Contacto:
- Maybelle De La Rosa
- Número de teléfono: 703-783-4518
- Correo electrónico: mdelarosa@nextoncology.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF.
-
Histologically confirmed advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on, was nonresponsive to, or for which no standard or available curative therapy exists.
- Participants in Phase 1 Backfill Cohorts & Phase 2 must be CDH17-positive by central testing.
- Other gastrointestinal (GI) tumor types may be enrolled in Backfill Cohorts and Phase 2.
-
At least 1 measurable target lesion at baseline per RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)
-
Provision of FFPE archival tumor tissue. Additional fresh biopsies at screening are required in Phase 1 Backfill Cohorts and Phase 2.
-
Adequate organ and marrow function as defined in the protocol
Exclusion Criteria:
-
Prior cancer treatment as follows, relative to the first planned dose of trial intervention:
- Chemotherapy or targeted therapy withing 4 weeks or 5-halflives (whichever is shorter)
- Monoclonal antibody-based therapy (including ADCs) within 4 weeks
- Immune checkpoint inhibitors within 4 weeks
- Wide-field radiation therapy (>30% marrow-bearing bones) within 4 weeks or < 2 weeks of focal palliative radiation to nontarget lesions
-
Prior treatment with a CDH17-directed therapy or an ADC with an auristatin (MMAE or MMAF)
-
Known hypersensitivity or allergic reaction to BHB810 or it's excipients
-
Left ventricular ejection fraction <50% or history of congestive heart failure Class III/IV
-
QTc interval > 470 msec, history of risk factors for Torsade de Pointes, or taking a medication known to prolong QT/QTc
-
Pregnant or breastfeeding females, or if you or your partner are planning to become pregnant
-
Known or suspected brain metastases, leptomeningeal disease, or spinal cord compression. Participants with stable, treated brain metastases may be enrolled.
-
Current treatment with a strong CYP3A4 inhibitor or inducer, Pgp inhibitor, or CYP3A4 sensitive substrate within 2 weeks of first dose of trial intervention
-
Any condition that may compromise participant safety, compliance, or interfere with the evaluation of the study drug.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Dose Escalation and Backfill Cohorts
Dose escalation and backfill cohorts |
Every 2 weeks IV administration |
|
Experimental: Recommended Phase 2 Dose Level 1 (RP2D1)
Dose level 1 of 2 prospective recommended phase 2 dose levels |
Every 2 weeks IV administration |
|
Experimental: Recommended Phase 2 Dose Level 2 (RP2D2)
Dose level 2 of 2 prospective recommended phase 2 dose levels |
Every 2 weeks IV administration |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs) per Common Terminology Criteria for Adverse Events v6.0 (CTCAE v6.0)
Periodo de tiempo: Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
|
Investigate the safety and tolerability of BHB810 by evaluation of AEs, SAEs, DLTs, and clinically significant changes safety assessments, like lab tests, vital signs, and other safety assessments Phase 1 (Dose Escalation & Backfill Cohorts) and Phase 2 (Dose Optimization) DLTs apply to Phase 1 Dose Escalation Cohorts only. |
Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
|
|
Incidence of participants who have a dose modification of BHB810 due to toxicity
Periodo de tiempo: Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
|
Investigate the safety and tolerability of BHB810 by assessment of dose modifications due to toxicity Phase 1 (Dose Escalation & Backfill Cohorts) |
Cycle 1 Day 1 through 30 days after the last dose, an average of 6 months
|
|
Overall Response Rate (ORR)
Periodo de tiempo: Screening through End of Treatment, an average of 6 months
|
Identify the recommended Phase 2 dose (RP2D) by comparing 2 doses of BHB810 by evaluating the ORR of participants according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Phase 2 (Dose Optimization) |
Screening through End of Treatment, an average of 6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Clinical Benefit Rate (CBR)
Periodo de tiempo: Screening through End of Treatment, an average of 6 months
|
Investigate preliminary antitumor activity of BHB810 as assessed by radiological response per RECIST v1.1 Number of participants who achieve stable disease (SD) for at least 6 months, or PR or CR for any duration Phase 1 (Dose Escalation & Backfill Cohorts) |
Screening through End of Treatment, an average of 6 months
|
|
Duration of Response (DOR)
Periodo de tiempo: Screening through End of Treatment or last scan, an average of 6 months
|
Investigate preliminary antitumor activity of BHB810 as assessed by radiological response per RECIST v1.1 Time from PR or CR to disease progression Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
Screening through End of Treatment or last scan, an average of 6 months
|
|
Progression Free Survival (PFS)
Periodo de tiempo: Screening through End of Treatment, an average of 6 months
|
Investigate preliminary antitumor activity of BHB810 as assessed by radiological response per RECIST v1.1 Time from first dose to first documented date of progression per RECIST v1.1 Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
Screening through End of Treatment, an average of 6 months
|
|
Overall Survival (OS)
Periodo de tiempo: Screening through End of Study, an average of 10 months
|
Investigate preliminary antitumor activity of BHB810 Time from first dose to death from any cause Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
Screening through End of Study, an average of 10 months
|
|
Pharmacokinetics: Area under the concentration-time curve (AUC)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Area under the concentration-time curve from zero to the end of a dosing interval at steady-state (AUC0-tau)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Maximum concentration of BHB810 (Cmax) Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Time to reach maximum drug concentration of BHB810 (Tmax)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Area under the concentration-time curve from zero to infinity (AUC0-inf)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Terminal elimination half-life (t1/2)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Volume of drug distribution during terminal phase (Vz)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Total body clearance of the drug (CL)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Pharmacokinetics: Area under the concentration-time curve from zero to last measurable concentration sample time (AUC0-last)
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the PK profile of BHB810 in blood samples Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
|
Incidence of antidrug antibodies (ADAs) in blood before and after BHB810 administration
Periodo de tiempo: At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
To characterize the ADAs and PK profile of BHB810 in blood samples Phase 1 (Dose Escalation & Backfill Cohorts) Phase 2 (Dose Optimization) |
At protocol defined intervals starting at Cycle 1 Day 1 through End of Treatment, an average of 6 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Neoplasias por sitio
- Enfermedades intestinales
- Neoplasias por tipo histológico
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del Estómago
- Neoplasias colorrectales
- Neoplasias Intestinales
- Neoplasias de glándulas endocrinas
- Enfermedades pancreáticas
- Neoplasias Glandulares y Epiteliales
- Enfermedades del Colon
- Carcinoma
- Neoplasias
- Neoplasias de Estómago
- Neoplasias colónicas
- Neoplasias pancreáticas
- Neoplasias Gastrointestinales
- Adenocarcinoma
Otros números de identificación del estudio
- BHB810-001
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .